<DOC>
	<DOC>NCT01128686</DOC>
	<brief_summary>This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.</brief_summary>
	<brief_title>Lamivudine(LAM) Good Responder Study</brief_title>
	<detailed_description>This is to evaluate the proportion of subjects who show good responses to LAM treatment such as HBV DNA negativity, HBV DNA less than 4 log, no resistant mutation, HBeAg seroconversion and normalization of ALT in naïve CHB patients with certain pre-treatment characteristics, i.e. HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive subjects, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative subjects.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1. CHB or liver cirrhosis due to Hepatitis B virus who had started LAM between Jan 1, 2003 and Dec 31, 2004 and maintained LAM at least 6 months 2. HBsAg positive at least for 6 months at the beginning of observation 3. HBV DNA positive before LAM administration 4. Subjects with certain pretreatment laboratory findings as follows; HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive patients, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative patients 1. Documented coinfection with HCV, HIV at the beginning of LAM treatment 2. Decompensated liver cirrhosis at the beginning of LAM treatment 3. HCC at the beginning of LAM treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>retrospective</keyword>
	<keyword>naïve Chronic Hepatitis B (CHB) patients</keyword>
	<keyword>cohort study</keyword>
	<keyword>lamivudine</keyword>
</DOC>